By Ana Espino | Published on January 30, 2026
| 3 min read
Hypertension (HTN) is a chronic cardiovascular disease
characterized by a sustained elevation of blood pressure. It is often silent
but strongly associated with severe complications, including stroke, myocardial
infarction, heart failure, and chronic kidney disease. It
represents one of the leading causes of preventable mortality worldwide.
Despite the availability of
effective treatments, management remains suboptimal, with many undiagnosed
patients, unachieved blood pressure targets, poor treatment
adherence, and overly uniform approaches. In addition, treatment
thresholds long set at 140/90 mmHg have often resulted in delayed
intervention.
To address these limitations, a new
strategy has been proposed: lowering diagnostic thresholds, integrating global
cardiovascular risk into therapeutic decision-making, and strengthening individualized
non-pharmacological interventions. This approach aims for earlier, more
precise, and more personalized prevention.
In this context, this study was
initiated to test this new strategy in order to improve the screening,
evaluation, and management of hypertension in adults, with a strong focus
on preventive and personalized medicine.
Should everyone aim for 130/80 mmHg?
These recommendations are based on a
systematic review of the literature evaluating diagnostic thresholds,
treatment benefits, blood pressure targets, and non-pharmacological
interventions. The level of evidence was graded using a standardized
system (Levels A to C).
The definition of hypertension has
been revised. A blood pressure of ≥130/80 mmHg (rather than 140/90 mmHg)
is now considered elevated, leading to an increase in diagnosed patients,
particularly among younger individuals. Cardiovascular risk stratification
is incorporated to guide treatment decisions. Patients with stage 1
hypertension but high cardiovascular risk (≥10% 10-year risk) should
receive pharmacological treatment, whereas others may initially benefit
from intensive lifestyle modifications.
Blood pressure targets have been
lowered to <130/80 mmHg for most patients, including older adults,
provided treatment is well tolerated. Antihypertensive therapy should be
tailored according to age, comorbidities, ethnic background,
and individual tolerance.
The importance of non-pharmacological
interventions is reinforced: the DASH diet, salt reduction, weight
loss, regular physical activity, alcohol moderation, and smoking
cessation are key pillars of blood pressure control. Finally, out-of-office
blood pressure monitoring (ambulatory or home measurements) is promoted to confirm
diagnosis, detect masked or white-coat hypertension, and better
assess treatment effectiveness.
Treat earlier, stratify better, prevent more
Hypertension is a common, silent
chronic disease responsible for major cardiovascular complications. Its
control remains insufficient worldwide due to late diagnosis, imperfect
risk stratification, and unequal access to care.
This study aimed to reassess
diagnostic thresholds and propose a preventive, personalized approach
based on global cardiovascular risk. It concludes that hypertension
management should start earlier, rely on more refined stratification,
and systematically integrate lifestyle interventions from the earliest
stages.
However, limitations remain
and justify further research. Future studies will include long-term
evaluations of the clinical and economic impact of the new thresholds, feasibility
studies in primary care, and analyses of patient adherence strategies
in the context of stricter targets. The challenge will be to confirm population-level
benefits while ensuring a realistic and equitable implementation of
these recommendations.
Read next: Holiday Heart: when alcohol takes
control of the heart’s rhythm
About the author – Ana Espino
PhD in Immunology, specialized in
Virology
As a scientific writer, Ana
is passionate about bridging the gap between research and real-world
impact. With expertise in immunology, virology, oncology, and clinical studies,
she makes complex science clear and accessible. Her mission: to accelerate
knowledge sharing and empower evidence-based decisions through impactful
communication.
